Patents by Inventor Christopher M. Snyder

Christopher M. Snyder has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • CMV-based intra-tumoral cancer therapies
    Patent number: 11351237
    Abstract: A CMV-based vaccine that promotes immune-mediated destruction of cancer through a onetime or repeated intratumoral administration of a recombinant CMV to generate a robust, long-lasting anti-tumor immune response.
    Type: Grant
    Filed: December 21, 2016
    Date of Patent: June 7, 2022
    Assignee: THOMAS JEFFERSON UNIVERSITY
    Inventors: Christopher M. Snyder, Daniel A. Erkes
  • INTRA-LESIONAL CMV-BASED CANCER VACCINES
    Publication number: 20200164054
    Abstract: A CMV-based vaccine that promotes immune-mediated destruction of cancer through a onetime or repeated intratumoral administration of a recombinant CMV to generate a robust, long-lasting anti-tumor immune response.
    Type: Application
    Filed: December 21, 2016
    Publication date: May 28, 2020
    Applicant: THOMAS JEFFERSON UNIVERSITY
    Inventors: Christopher M. SNYDER, Daniel A. ERKES
  • CYTOMEGALOVIRUS-BASED IMMUNOGENIC PREPARATIONS
    Publication number: 20160220650
    Abstract: Methods of using recombinant replication-deficient cytomegalovirus (CMV) to generate a long-term, repeatedly stimulated immune response in a subject, for instance against a heterologous antigen expressed by the cytomegalovirus, are described. Also described are methods of using a recombinant replication deficient CMV as an anti-cancer immunogenic preparation.
    Type: Application
    Filed: April 19, 2016
    Publication date: August 4, 2016
    Applicant: Oregon Health & Science University
    Inventors: Ann B. Hill, Christopher M. Snyder
  • CYTOMEGALOVIRUS-BASED IMMUNOGENIC PREPARATIONS
    Publication number: 20120289760
    Abstract: This disclosure relates to methods of using recombinant replication-deficient cytomegalovirus (CMV) to generate a long-term, repeatedly stimulated T cell-based immune response in a subject, for instance against a heterologous antigen expressed by the cytomegalovirus. It further relates to methods of using a recombinant replication deficient CMV as an anti-cancer immunogenic preparation.
    Type: Application
    Filed: January 27, 2010
    Publication date: November 15, 2012
    Inventors: Ann B. Hill, Christopher M. Snyder